Fengate Buys Majority Stake in Clearwater Trial Site
Clinical research operators in the Tampa Bay area should watch for new infrastructure investment and Southeast site partnerships.
Updated on Nov. 2, 2026 in Healthcare
Live Poll
Do you trust private equity firms to improve local healthcare providers?
Fengate Private Equity has acquired a majority stake in Clinical Research of West Florida, a clinical trial company operating three research facilities in Clearwater and Tampa. Financial terms were not disclosed, and the deal marks Fengate's second pharma services platform investment.
Why it matters
The acquisition brings additional private capital into a clinical research site network that has supported more than 1,000 trials and screened more than 12,000 patients. For operators in the Clearwater and Tampa Bay healthcare and research sector, it signals continued investor interest in site-based trial services as sponsors seek capacity.
Clinical Research of West Florida reports 30 years of operations, three facilities, more than 1,000 supported trials, and nearly 300 sponsor and CRO relationships. Fengate's portfolio includes more than nine investments, and this is its second pharma services platform deal, though the price was not disclosed.
The players
Fengate Private Equity
A division of Fengate Asset Management based in Toronto that invests in lower middle-market businesses across North America.
Clinical Research of West Florida
A Tampa Bay-area clinical trial company operating three research facilities in Clearwater and Tampa with a 30-year operating history.
LiUNA Pension Fund of Central and Eastern Canada
A pension fund whose investment is managed by Fengate Private Equity.
The details
Fengate Private Equity, a division of Fengate Asset Management headquartered in Toronto, manages the investment on behalf of the LiUNA Pension Fund of Central and Eastern Canada. Fengate targets lower middle-market businesses across North America. Clinical Research of West Florida plans to invest in capabilities and infrastructure, develop new sites, and partner with independent research sites across the Southeast.
Timeline
Article about the acquisition published November 2, 2026; the transaction's closing date was not specified in the source.
Market Landscape
Fengate's second pharma services platform investment places it among private equity firms consolidating outsourced clinical research capacity at the mid-market level. The deal reflects continued private capital interest in site-based clinical trial operations rather than only large contract research organizations.
Clinical research sites and their staff in the Clearwater and Tampa area should watch for expansion plans and partnership opportunities with independent sites in the Southeast. Operators who coordinate with trial sponsors should factor in possible changes to site capacity and vendor relationships as the new owner invests in infrastructure.
The takeaway
Private ownership of research sites often brings planned investment in capacity, so operators should track whether Clinical Research of West Florida expands its facilities or partner network. Businesses that depend on trial site services should request updated capability and capacity information from current vendors.
Further reading
For more on the sector behind this deal, explore Healthcare coverage of trial sites and outsourced research in the Clearwater area.
Source note: This article includes information reported by St Pete Catalyst.
Live Poll
Do you trust private equity firms to improve local healthcare providers?
